Even though high-dose paclitaxel formulated conventionally demonstrated no benefit of tumor response and survival with more relevant toxicities in breast cancer (18), nanoparticle albumin-bound paclitaxel showed higher response rates with acceptable toxicities in breast, lung, and pancreatic cancers, suggesting that it could improve drug distribution in the body while inducing rapid elimination from serum (19–21). This evidence concerns the gene ALB and familial pancreatic carcinoma.